Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Advanced Solid Tumor|Metastatic Melanoma|Metastatic Head and Neck Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Colorectal Cancer|Sarcomas|Metastatic Prostate Cancer|Ovarian Cancer|Small Cell Lung Cancer|Metastatic Breast Cancer|Pancreas Cancer|Gastric Cancer|Esophageal Cancer|Gastroesophageal Junction Adenocarcinoma|Cervical Cancer|Adenoid Cystic Carcinoma|Salivary Gland Cancer|Urothelial Carcinoma
Interventions: DRUG: ONC-392|DRUG: Pembrolizumab
Sponsor: OncoC4, Inc.
Collaborators: National Cancer Institute (NCI)